{"id":226792,"date":"2026-09-02T10:12:26","date_gmt":"2026-09-02T04:42:26","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=226792"},"modified":"2026-10-01T09:53:40","modified_gmt":"2026-10-01T04:23:40","slug":"why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/","title":{"rendered":"Astrazeneca Pharma India Ltd. (ASTRAZEN) 52 Week Low Streak: Second Straight Session, Rs 2.19% Drop"},"content":{"rendered":"<div class=\"univest-blue-summary\" style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:12px 16px;margin:0 0 18px 0;font-style:italic;\"><em><a href=\"https:\/\/univest.in\/stocks\/astrazen\/astrazeneca-pharma-india-ltd-share-price-today\">Astrazeneca Pharma India Ltd. (ASTRAZEN)<\/a> share price fell to a fresh 52-week low of Rs 6,084.05 today and later stood at Rs 6,117.55, down 1.15% from the previous close. Market cap was Rs 15,471.88 crore.<\/em><\/div>\n<p style=\"margin-top:0!important;\">Astrazeneca Pharma India Ltd. has now set a fresh 52-week low for its second straight session, extending a decline of 2.19% across the streak to a latest trough of Rs 6,084.05. The stock closed at Rs 6,117.55, and Univest data confirms the repeated-low pattern but does not establish a company-specific cause for the continued move. For readers tracking Astrazeneca Pharma India Ltd. 52 Week Low Streak, the key point is the persistence of the breakdown rather than just the latest daily move.<\/p>\n<p>With a market capitalisation of Rs 15,471.88 crore, Astrazeneca Pharma India Ltd. remains a sizeable healthcare company even as the repeated-low pattern keeps the share price under pressure. A second straight fresh yearly low is more informative than a single-day break because it shows the decline has carried forward into another session. For investors, Astrazeneca Pharma India Ltd. 52 Week Low Streak is therefore a signal to watch the depth and continuity of the move, not to treat it as an isolated price event.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_Consecutive_Low_Analysis\" title=\"Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis\">Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#What_the_Repeated_52-Week_Lows_Show\" title=\"What the Repeated 52-Week Lows Show\">What the Repeated 52-Week Lows Show<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Astrazeneca_Pharma_India_Ltd_ASTRAZEN_Fundamental_Analysis\" title=\"Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis\">Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Sector_and_Industry_Context\" title=\"Sector and Industry Context\">Sector and Industry Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Peer_Comparison\" title=\"Peer Comparison\">Peer Comparison<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Why_Investors_Are_Watching\" title=\"Why Investors Are Watching\">Why Investors Are Watching<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#About_the_Company\" title=\"About the Company\">About the Company<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Track_Astrazeneca_Pharma_India_Ltd_Share_Price_on_Univest\" title=\"Track Astrazeneca Pharma India Ltd. Share Price on Univest\">Track Astrazeneca Pharma India Ltd. Share Price on Univest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#What_does_Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_mean\" title=\"What does Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?\">What does Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#How_many_sessions_has_Astrazeneca_Pharma_India_Ltd_set_a_fresh_52-week_low\" title=\"How many sessions has Astrazeneca Pharma India Ltd. set a fresh 52-week low?\">How many sessions has Astrazeneca Pharma India Ltd. set a fresh 52-week low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#What_is_the_latest_52-week_low_for_Astrazeneca_Pharma_India_Ltd\" title=\"What is the latest 52-week low for Astrazeneca Pharma India Ltd.?\">What is the latest 52-week low for Astrazeneca Pharma India Ltd.?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#How_does_Astrazeneca_Pharma_India_Ltd_look_on_valuation_after_the_streak\" title=\"How does Astrazeneca Pharma India Ltd. look on valuation after the streak?\">How does Astrazeneca Pharma India Ltd. look on valuation after the streak?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#How_does_the_company_compare_with_the_healthcare_sector\" title=\"How does the company compare with the healthcare sector?\">How does the company compare with the healthcare sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#Why_is_the_repeated_52-week_low_more_important_than_a_single-day_dip\" title=\"Why is the repeated 52-week low more important than a single-day dip?\">Why is the repeated 52-week low more important than a single-day dip?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/why-astrazeneca-pharma-india-ltd-share-52-week-consecutive-low-2026\/#What_should_investors_monitor_next\" title=\"What should investors monitor next?\">What should investors monitor next?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_Consecutive_Low_Analysis\"><\/span><strong>Astrazeneca Pharma India Ltd. 52 Week Low Streak: Consecutive Low Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Current Price<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,117.55<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Previous Close<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,188.75<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Today&#39;s Move<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs -71.2 (-1.15%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Open<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,133<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>High<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,154.05<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Low<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 6,084.05<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 15,471.88 crore<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,117.55 versus the previous close of Rs 6,188.75, a fall of 1.15%. The stock opened at Rs 6,133, reached a high of Rs 6,154.05, touched a low of Rs 6,084.05.<\/p>\n<p>Astrazeneca Pharma India Ltd. 52 Week Low Streak extended through another weak session, with the stock ending at Rs 6,117.55 against the previous close of Rs 6,188.75. That left the share price down Rs 71.20, or 1.15%, on the day. The open at Rs 6,133.00 was below the prior close, and the stock moved between Rs 6,154.05 and Rs 6,084.05 during the session, finishing near the lower end of that range. The close at Rs 6,117.55 sat just above the intraday low, which kept Astrazeneca Pharma India Ltd. 52 Week Low Streak in focus for market participants watching the latest yearly low.<\/p>\n<p>The session matters because it shows Astrazeneca Pharma India Ltd. 52 Week Low Streak was not limited to a single intraday dip. The day\u2019s low matched the fresh 52-week trough, while the close remained only modestly above it. Market capitalisation stood at Rs 15,471.88 crore, giving context to the decline in a stock that still sits within a large listed healthcare business. For readers, Astrazeneca Pharma India Ltd. 52 Week Low Streak is best read as a continued downward reset in price rather than a one-off slip.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_the_Repeated_52-Week_Lows_Show\"><\/span><strong>What the Repeated 52-Week Lows Show<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Astrazeneca Pharma India Ltd. 52 Week Low Streak now reflects two consecutive sessions of fresh one-year lows, which makes the pattern more important than the latest close alone. The first breakdown on 30 September 2026 is now followed by another lower finish, and the cumulative decline across the streak has reached 2.19%. That cumulative move is the central number for Astrazeneca Pharma India Ltd. 52 Week Low Streak because it captures the full run, not just the final daily change.<\/p>\n<p>The current low of Rs 6,084.05 is the new reference point for the market. Because Univest data does not supply a previous 52-week low beyond the current trough, Astrazeneca Pharma India Ltd. 52 Week Low Streak should be read using the observed streak itself rather than a comparison with an earlier low level. The latest Univest data confirms the repeated yearly-low pattern, but it does not confirm a company-specific reason. In practical terms, Astrazeneca Pharma India Ltd. 52 Week Low Streak tells readers that the downside has persisted into a second session and that the market is still repricing the stock lower.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Astrazeneca_Pharma_India_Ltd_ASTRAZEN_Fundamental_Analysis\"><\/span><strong>Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 15,471.88 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">91.21x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">17.11x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">23.02%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">31.24%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>EPS<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 67.85<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Book Value Per Share<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 361.68<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Dividend Yield<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0.58%<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P\/E 91.21x, P\/B 17.11x, ROE 23.02%, ROCE 31.24%. These ratios show where the company stands today and are not a call to buy or sell.<\/p>\n<p>Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 15,471.88 crore, which gives readers a sense of company size before judging valuation. On valuation, P\/E at 91.21x, P\/B at 17.11x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.58%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P\/E of 32.01x, median ROE of 11.7%, median ROCE of 13.46%. Together they describe the fundamental backdrop without implying a buy or sell view.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sector_and_Industry_Context\"><\/span><strong>Sector and Industry Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Sector<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Healthcare<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Industry<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Pharmaceuticals &amp; Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Scope<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">same industry<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">91.21x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">32.01x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Average P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">48.92x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark P\/E Range<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">3.4x to 688.17x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">17.11x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/B<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.92x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">23.02%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">11.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">31.24%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">13.46%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 15,471.88 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median Market Cap<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 765.11 crore<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) operates in the Healthcare sector, within the Pharmaceuticals &amp; Drugs industry.<\/p>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P\/E ratio of 91.21x, which is above the benchmark median of 32.01x, a difference of +184.94%. A P\/E difference of this kind is a reference point rather than a recommendation.<\/p>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.46%, a difference of +132.1%.<\/p>\n<p>Track stocks falling to yearly lows through the <a href=\"https:\/\/univest.in\/screeners\/52-week-low\">Univest 52-week-low screener<\/a>. The peer table below provides the company-level comparison.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Peer_Comparison\"><\/span><strong>Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Company<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Symbol<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Market Cap (Cr)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/E<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/B<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROE (%)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROCE (%)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Marksans Pharma Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">MARKSANS<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15,534.45<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">28.26<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.59<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15.31<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">21.1<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Natco Pharma Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">NATCOPHARM<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">15,115.98<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">12.94<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">1.59<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16.3<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">17.16<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Concord Biotech Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">CONCORDBIO<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">14,750.36<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">52.18<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">6.93<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">13.54<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">18.04<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/jublpharma\/jubilant-pharmova-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Jubilant Pharmova Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">JUBLPHARMA<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16,719.74<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">46.54<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2.3<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">5.97<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">8.69<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/eris\/eris-lifesciences-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Eris Lifesciences Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">ERIS<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">16,904.6<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">25.64<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.09<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">19.23<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">14.47<\/td>\n<\/tr>\n<\/table>\n<p>Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P\/E ratio of 91.21x compared with the displayed peer median of 28.26x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 17.16%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 15,471.88 crore. Among the 5 peers shown, 3 have a larger market capitalisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching\"><\/span><strong>Why Investors Are Watching<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Astrazeneca Pharma India Ltd. 52 Week Low Streak has now run for two consecutive sessions, which makes the pattern more meaningful than a single-day break.<\/li>\n<li>The cumulative decline across Astrazeneca Pharma India Ltd. 52 Week Low Streak is 2.19%, giving a clearer view of the full move.<\/li>\n<li>The latest low of Rs 6,084.05 is the new reference point for traders and long-term readers watching Astrazeneca Pharma India Ltd. 52 Week Low Streak.<\/li>\n<li>Valuation remains elevated at 91.21 times earnings and 17.11 times book, even after Astrazeneca Pharma India Ltd. 52 Week Low Streak.<\/li>\n<li>The stock still compares differently from peers and sector medians, so Astrazeneca Pharma India Ltd. 52 Week Low Streak remains a valuation story as much as a price story.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"About_the_Company\"><\/span><strong>About the Company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Astrazeneca Pharma India Ltd. operates in Pharmaceuticals &amp; Drugs within the Healthcare sector. For readers tracking Astrazeneca Pharma India Ltd. 52 Week Low Streak, the relevant business context is its position as a listed pharmaceutical company with a sizeable market capitalisation and a premium valuation profile. The company\u2019s reported ROE, ROCE, EPS and book value show that the business remains established, even though the share price has moved to a fresh 52-week low again.<\/p>\n<p>That context matters because Astrazeneca Pharma India Ltd. 52 Week Low Streak should not be read as a question about business existence or scale. It is a question about how the market is pricing a healthcare company whose current multiples remain above peers and industry medians. The article therefore focuses on the streak, the valuation and the sector position rather than a generic company profile.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Track_Astrazeneca_Pharma_India_Ltd_Share_Price_on_Univest\"><\/span><strong>Track Astrazeneca Pharma India Ltd. Share Price on Univest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use <a href=\"https:\/\/univest.in\/stocks\/astrazen\/astrazeneca-pharma-india-ltd-share-price-today\">Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page<\/a>, <a href=\"https:\/\/univest.in\/screeners\/52-week-low\">Univest 52-week-low screener<\/a>, <a href=\"https:\/\/univest.in\/blogs\">Univest market blogs<\/a> to review live stock data, yearly-low lists and related market analysis.<\/p>\n<p>Astrazeneca Pharma India Ltd. 52 Week Low Streak is best followed alongside the next close, because consecutive lows can change the market\u2019s reference point quickly. Readers tracking Astrazeneca Pharma India Ltd. 52 Week Low Streak can monitor the share price, valuation ratios and sector comparison on the company\u2019s stock page to see whether the price keeps printing lower yearly levels or stabilises around the current trough.<\/p>\n<p>The most useful watchlist for Astrazeneca Pharma India Ltd. 52 Week Low Streak is simple: the latest close, the next 52-week low reference and the way the valuation compares with the same industry and peer set. Those are the variables that shape the streak story.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Astrazeneca_Pharma_India_Ltd_52_Week_Low_Streak_mean\"><\/span><strong>What does Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It means Astrazeneca Pharma India Ltd. has set a fresh 52-week low in consecutive sessions. In this case, the streak has reached a second straight session, which makes the decline more notable than a one-day move.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_many_sessions_has_Astrazeneca_Pharma_India_Ltd_set_a_fresh_52-week_low\"><\/span><strong>How many sessions has Astrazeneca Pharma India Ltd. set a fresh 52-week low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock has set a fresh 52-week low for two consecutive sessions.The stock moved -1.15% during the session.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_latest_52-week_low_for_Astrazeneca_Pharma_India_Ltd\"><\/span><strong>What is the latest 52-week low for Astrazeneca Pharma India Ltd.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong>05. That level was also the day\u2019s low in the most recent session, which keeps the streak active. The stock moved -1.15% during the session.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Astrazeneca_Pharma_India_Ltd_look_on_valuation_after_the_streak\"><\/span><strong>How does Astrazeneca Pharma India Ltd. look on valuation after the streak?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock trades at 91.21 times earnings and 17.11 times book.The company trades at a P\/E ratio of 91.21x.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_the_company_compare_with_the_healthcare_sector\"><\/span><strong>How does the company compare with the healthcare sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Its P\/E and P\/B are well above the sector medians, while ROE and ROCE are also stronger than the industry medians. That means the stock is still priced at a premium relative to the sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_the_repeated_52-week_low_more_important_than_a_single-day_dip\"><\/span><strong>Why is the repeated 52-week low more important than a single-day dip?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Two consecutive lows show that the weakness carried forward into another session. That makes Astrazeneca Pharma India Ltd. 52 Week Low Streak more informative than a one-day break in isolation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_monitor_next\"><\/span><strong>What should investors monitor next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should watch whether the stock trades below the current low again, how the close behaves near Rs 6,084.05, and whether valuation multiples continue to compress as the streak develops.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does Astrazeneca Pharma India Ltd. 52 Week Low Streak mean?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It means Astrazeneca Pharma India Ltd. has set a fresh 52-week low in consecutive sessions. In this case, the streak has reached a second straight session, which makes the decline more notable than a one-day move.\"}},{\"@type\":\"Question\",\"name\":\"How many sessions has Astrazeneca Pharma India Ltd. set a fresh 52-week low?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock has set a fresh 52-week low for two consecutive sessions. the streak label is \u201csecond straight session,\u201d so the pattern is confirmed across both trading days. The stock moved -1.15% during the session.\"}},{\"@type\":\"Question\",\"name\":\"What is the latest 52-week low for Astrazeneca Pharma India Ltd.?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The latest 52-week low supplied is Rs 6,084.05. That level was also the day\u2019s low in the most recent session, which keeps the streak active. The stock moved -1.15% during the session.\"}},{\"@type\":\"Question\",\"name\":\"How does Astrazeneca Pharma India Ltd. look on valuation after the streak?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock trades at 91.21 times earnings and 17.11 times book. Those multiples remain above the supplied healthcare and peer benchmarks even after the latest decline. The company trades at a P\/E ratio of 91.21x.\"}},{\"@type\":\"Question\",\"name\":\"How does the company compare with the healthcare sector?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Its P\/E and P\/B are well above the sector medians, while ROE and ROCE are also stronger than the industry medians. That means the stock is still priced at a premium relative to the sector.\"}},{\"@type\":\"Question\",\"name\":\"Why is the repeated 52-week low more important than a single-day dip?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Two consecutive lows show that the weakness carried forward into another session. That makes Astrazeneca Pharma India Ltd. 52 Week Low Streak more informative than a one-day break in isolation.\"}},{\"@type\":\"Question\",\"name\":\"What should investors monitor next?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should watch whether the stock trades below the current low again, how the close behaves near Rs 6,084.05, and whether valuation multiples continue to compress as the streak develops.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Astrazeneca Pharma India Ltd. Share Price hit a fresh 52-week low of Rs 6,084.05 for the second straight session and is trading at Rs 6,117.55, down 1.15% on the day. Market cap stands at Rs 15,471.88 crore.<\/p>\n","protected":false},"author":35,"featured_media":282448,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-226792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["282448"],"rank_math_title":["Astrazeneca Pharma India Consecutive 52 Week Low Pattern"],"rank_math_description":["Astrazeneca Pharma India has now set a fresh 52-week low for a second straight session. See the streak move, valuation, sector context and peers."],"rank_math_focus_keyword":["Astrazeneca Pharma India Ltd. 52 Week Low Streak"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/Astrazeneca_Pharma_India_Ltd_ASTRAZEN_52_Week_Low_Streak_Second_Straight_Session_Rs_219_Drop_bearish.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/226792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=226792"}],"version-history":[{"count":3,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/226792\/revisions"}],"predecessor-version":[{"id":282451,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/226792\/revisions\/282451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/282448"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=226792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=226792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=226792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}